Lexaria Bioscience warrants exercised at reduced price of USD 12.92 per share

PUBT · 2d ago
Lexaria Bioscience warrants exercised at reduced price of USD 12.92 per share
  • Lexaria entered agreements for immediate cash exercise of warrants covering 453,969 common shares at a reduced $12.92 per share.
  • Gross proceeds expected at about $5.9 million, before fees; closing expected on or about Sept. 9, 2026.
  • Incentive package includes unregistered Series A warrants for 453,969 shares, exercisable immediately at $12.67; expiry five years post resale statement effectiveness.
  • Short-term unregistered Series B warrants for 453,969 shares, exercisable immediately at $12.67; expiry 18 months post resale statement effectiveness.
  • Company plans to file a resale registration statement covering shares issuable on exercise of the new warrants.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Lexaria Bioscience Corp. published the original content used to generate this news brief via ACCESS Newswire (Ref. ID: 202609080800ACCESSWRNAPR_____1217930) on September 08, 2026, and is solely responsible for the information contained therein.